ZURICH, July 12 Europe's leading biotech company
Actelion said on Thursday it planned to cut up to 135
jobs as part of cost-cutting to focus on research in pulmonary
arterial hypertension, or PAH.
Actelion, which employs 2500 people globally, has been
banking on lung and heart drug macitentan as a successor to its
blockbuster Tracleer, which currently accounts for around 90
percent of group sales and goes off patent in 2015.
The firm said it was minimising the number of potential
redundancies through natural attrition, early retirements and
(Reporting by Catherine Bosley)